Medical management of HIV-hepatitis C virus coinfection in injection drug users

Clinical Infectious Diseases

Volumn 41, Issue 1 SUPPL., 2005, Pages

  Khalsa, Jag H ^a   Kresina, Tom ^a   Sherman, Ken ^b   Vocci, Francis ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; BUPRENORPHINE; CYTOCHROME P450 3A4; EFAVIRENZ; ENVELOPE PROTEIN; ENZYME INHIBITOR; HELICASE; HISTAMINE; ILLICIT DRUG; METHADONE; PEGINTERFERON; PROTEINASE INHIBITOR; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SERINE PROTEINASE INHIBITOR; STAVUDINE; THYMOSIN; VIRUS ANTIBODY; VIRUS RNA;

CELLULAR IMMUNITY; CHRONIC LIVER DISEASE; CLINICAL TRIAL; COMORBIDITY; DISEASE ASSOCIATION; DRUG ABUSE; DRUG DEPENDENCE; DRUG USE; GENOTYPE; HEALTH CARE PERSONNEL; HEPATITIS C VIRUS; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTIOUS HEPATITIS; LIVER CIRRHOSIS; LIVER DISEASE; LIVER INJURY; LIVER TRANSPLANTATION; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SIDE EFFECT; VIRUS HEPATITIS;

DISEASE MANAGEMENT; HEPATITIS C; HIV INFECTIONS; HUMANS; INCIDENCE; PREVALENCE; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 20844446475     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/429488     Document Type: Review

References (39)

1. Joint United Nations Programme on HIV/AIDS, World Health Organization. AIDS epidemic update, 2004. Document no. UNAIDS/01.74E-WHO/CS/CSR/NCS 2004. Geneva: World Health Organization, 2004.
2. Joint United Nations Programme on HIV/AIDS, World Health Organization. Hepatitis C status. Geneva: World Health Organization, 1998.
3. Substance Abuse and Mental Health Services Administration. Overview of findings from the 2003 National Survey on Drug Use and Health. NSDUH series H-24, DHHS publication no. SMA 04-3963. Rockvilie, MD: Department of Health and Human Services, 2004.
4. Thomas DL. Hepatitis C and human immunodeficiency virus infection. Hepatology2002; 36(Suppl 1):S201-9.
5. Strader DB. Understudied populations with hepatitis C. Hepatology 2002; 36(Suppl 1): S226-36.
6. Strader DB. Coinfection with HIV and hepatitis C virus in injection drug users and minorities. Clin Infect Dis 2005; 41(Suppl 1): S7-13 (in this issue).
7. Garten RJ, Zhang J, Lai S, Liu W, Chen J, Yu XF. Coinfection with HIV and hepatitis C virus among injection drug users in southern China. Clin Infect Dis 2005; 41(Suppl 1): S18-24 (in this issue).
8. Chung R. Acute hepatitis C virus infection. Clin Infect Dis 2005; 41(Suppl 1):S14-7 (in this issue).
9. Koziel MJ. Cellular immune responses against hepatitis C virus. Clin Infect Dis 2005; 41(Suppl 1):S25-31 (in this issue).
10. Balasubramanian A, Koziel M, Groopman JE, Ganju RK. Molecular mechanisms of hepatic injury in Coinfection with hepatitis C virus and HIV. Clin Infect Dis 2005; 41(Suppl 1): S32-7 (in this issue).
11. Munshi N, Balasubramanian A, Koziel M, Ganju RK, Groopman JE. Hepatitis C and human immunodeficiency virus envelope proteins cooperatively induce hepatocytic apoptosis via an innocent bystander mechanism. J Infect Dis 2003; 188:1192-204.
12. Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 2002; 35: 440-6.
13. Hilsabeck RC, Costellon SA, Hinkin CH. Neuropsychological aspects of Coinfection with HIV and hepatitis C virus. Clin Infect Dis 2005; 41(Suppl 1):S38-44 (in this issue).
14. Hinkin CH, van Gorp WG, Satz P. Neuropsychological aspects of HIV infection. In: Kaplan HI, Sadock BJ, eds. The comprehensive textbook of psychiatry. Vol VI. Baltimore: Williams & Wilkins, 1995:1669-80.
15. Gonzalez R, Jacobs J, Martin EM. Investigating neurocognitive features of hepatitis C virus infection in drug users: potential challenges and lessons learned from the HIV literature. Clin Infect Dis 2005; 41(Suppl 1):S45-9 (in this issue).
16. Neff GW, Shire NJ, Rudich SM. Outcomes among patients with end-stage liver disease who are coinfected with HIV and hepatitis C virus. Clin Infect Dis 2005; 41(Suppl 1):S50-5 (in this issue).
17. Soriano V, Garcia-Samaniego J, Rodriguez-Rosado R, Gonzalez J, Pedreira J. Hepatitis C and HIV infection: biological, clinical, and therapeutic implications. J Hepatol 1999; 31(Suppl 1):119-23.
18. Soriano V, Garcia-Samaniego J, Valencia E, Rodriguez-Rosado R, Munoz F, Gonzalez-Lahoz J. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999; 15:1-4.
19. Spital A. Should all human immunodeficiency virus-infected patients with end-stage renal disease be excluded from transplantation? The views of US transplant centers. Transplantation 1998; 65:1187-91.
20. National Institutes of Health. Management of hepatitis C. National Institutes of Health Consensus Development Conference Statement, 2002. Bethesda, MD: National Institutes of Health, 2002.
21. McGovern B, Fiore J, Wurcel A, et al. Delivering therapy for hepatitis C virus to incarcerated HIV-seropositive patients. Clin Infect Dis 2005; 41(Suppl 1):S56-62 (in this issue).
22. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV cohort study. Lancet 2000; 356:1800-5.
23. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492-7.
24. Shire NJ, Sherman KE. Clinical trials of treatment for hepatitis C virus infection in HIV-infected patients: past, present, and future. Clin Infect Dis 2005; 41(Suppl 1):S63-8 (in this issue).
25. Cooper CL. Therapeutic interventions for HIV infection and chronic viral hepatitis. Clin Infect Dis 2005; 41(Suppl 1):S69-72 (in this issue).
26. Conway B, Grebely J, Tossonian H, Lefebvre D, de Vlaming S. A systematic approach to the treatment of HIV and hepatitis C virus infection in the inner city: a Canadian perspective. Clin Infect Dis 2005; 41(Suppl 1): S73-8 (in this issue).
27. Alter MJ, Moyer LA. The importance of preventing hepatitis C virus infection among injecting drug users in the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18(Suppl 1):S6-10.
28. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34: 188-93.
29. Dalgard O, Bjoro K, Helium K, et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Construct Group. Eur Addict Res 2002; 8:45-9.
30. Sylvestre DL. Injecting drug use and hepatitis C: from transmission to treatment. Psych Ann 2003; 33:377-82.
31. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002; 67:117-23.
32. Sylvestre DL. Approaching treatment for hepatitis C virus in substance users. Clin Infect Dis 2005; 41(Suppl 1):S79-82 (in this issue).
33. Kresina TF, Bruce RD, Cargill VA, Cheever LW. Integrating care for hepatitis C virus (HCV) with primary care for HIV for injection drug users coinfected with HIV and HCV. Clin Infect Dis 2005; 41(Suppl 1):S83-8 (in this issue).
34. McCance-Katz EF. Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents. Clin Infect Dis 2005; 41(Suppl 1):S89-95 (in this issue).
35. McCance-Katz EF, Gourevitch MN, Arnsten J, Sarlo J, Rainey P, Jatlow P. Modified directly observed therapy (MDOT) for injection drug users with HIV disease. Am J Addict 2002; 11: 271-8.
36. McCance-Katz EF, Rainey P, Friedland G, Jatlow P. The protease inhibitor lopinavir/ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis 2003; 37:476-82.
37. McCance-Katz EF, Pade P, Exhem-Williams C, Hellew L, Moody D, Rainey PM. Concomitant administration of buprenorphine and efavirenz is not associated with opiate abstinence symptoms in opioid dependent individuals. Drug Alcohol Depend (in press).
38. Bean P. New drug targets for HIV. Clin Infect Dis 2005; 41(Suppl 1):S96-100 (in this issue).
39. Tedaldi EM. New drug targets for HIV and hepatitis C virus coinfection. Clin Infect Dis 2005; 41(Suppl 1):S105-9 (in this issue).